Novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were synthesized and (
S)-7-(2-{2-[(
E)-2-cyclopentylvinyl]-5-methyloxazol-4-yl}ethoxy)-2-[(2
E,4
E)-hexadienoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (
14c) was identified as a peroxisome proliferator-activated receptor (PPAR) α/γ dual agonist. The transactivation activity of
14c was comparable to that of rosiglitazone in human PPARγ (EC
50=0.14 μ
M) and was much higher than in human PPARα (EC
50=0.20 μ
M). In addition,
14c, but not rosiglitazone, showed human protein-tyrosine phosphatase 1B (PTP-1B) inhibitory activity (IC
50=1.85 μ
M).
14c showed about 10-fold stronger hypoglycemic and hypotriglyceridemic effects than rosiglitazone by repeated application for 14 d in male KK-A
y mice. Furthermore,
14c, but not rosiglitazone, increased hepatic peroxisome acyl CoA oxidase activity at 30 mg/kg/d for 7 d in male Syrian hamsters, probably due to its PPARα agonist activity.
14c did not affect plasma volume at 100 mg/kg/d for 14 d in male ICR mice, while rosiglitazone significantly increased it. In conclusion,
14c is a promising candidate for an efficacious and safe anti-diabetic drug with triple actions as a PPARα/γ dual agonist with PTP-1B inhibitory activity.
View full abstract